[Effectiveness of Broncho-Vaxom in prevention of recurrent upper respiratory tract infection in children].
OBJECTIVE
Evaluation of effectiveness of immunostimulating treatment with Broncho-Vaxom and his influence on concentration of proinflammatory cytokines in children with recurrent upper respiratory tract infection.


METHODS
The study comprised 32 children (the average age 8 years and 4 months) with recurrent upper respiratory tract infection received immunostimulating treatment with Broncho-Vaxom. 20 children (the average age 7 years and 8 months) with recurrent upper respiratory tract infection which did not receive treatment with Broncho-Vaxom consisted the control group. In all children clinical state and concentration of cytokines TNF-alpha and, IL-1beta, IL-6, IL-8 in serum was examined. Period of observation in both groups carried out 24 months. Follow-up was executed after 6 months.


RESULTS
In children treated with Broncho-Vaxom statistically significant (p<0.01) decrease in frequency of occurrence as well as shortening of duration of upper respiratory tract infection were observed. In children treated with Broncho-Vaxom statistically significant (p<0.01) decrease of serum concentration of TNF-alpha and in time of observation. The statistically significant changes were not observed in serum concentrations IL-1beta in time of observation. It was statistically significant (p<0.01) affirmed the rise of serum concentration of IL-6 in time of observation, the largest growth of concentration this cytokine stepped out in 1 year of treatment. The statistically significant (p<0.01) increase of concentration cytokine IL-8 in the first year of treatment as well as statistically significant (p<0.05) decrease of concentration this cytokine after end of treatment.


CONCLUSIONS
The treatment with Broncho-Vaxom shows the high effectiveness in prevention of recurrent upper respiratory tract infection in children as well as the influences of profitable changes in profile of serum cytokines which can impact on limitation the inflammation process in the upper respiratory tract.
Zielnik-Jurkiewicz
Beata
B
Oddzial Otolaryngologiczny Samodzielnego Zespołu Publicznych Zakładów Opieki Zdrowotnej w Warszawie. bzielnik@lekarz.net
Jurkiewicz
Dariusz
D
Stankiewicz
Wanda
W
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001419:Bacteria; D002457:Cell Extracts / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005334:Fever / Q000453:epidemiology; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D015995:Prevalence; D012141:Respiratory Tract Infections / Q000453:epidemiology / Q000517:prevention & control*; D055502:Secondary Prevention; D000095983:Bacterial Lysates
D000276:Adjuvants, Immunologic; D002457:Cell Extracts; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates